Pulike Biological Engineering Past Earnings Performance
Past criteria checks 0/6
Pulike Biological Engineering's earnings have been declining at an average annual rate of -2.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 11% per year. Pulike Biological Engineering's return on equity is 3.9%, and it has net margins of 9.4%.
Key information
-2.1%
Earnings growth rate
-4.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 11.0% |
| Return on equity | 3.9% |
| Net Margin | 9.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture
Sep 04
Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump
May 21Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024
Apr 28Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E
Mar 21Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly
Feb 28Revenue & Expenses Breakdown
How Pulike Biological Engineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,086 | 102 | 462 | 109 |
| 30 Jun 24 | 1,118 | 132 | 459 | 104 |
| 31 Mar 24 | 1,181 | 138 | 485 | 104 |
| 31 Dec 23 | 1,253 | 175 | 478 | 101 |
| 30 Sep 23 | 1,331 | 219 | 480 | 104 |
| 30 Jun 23 | 1,335 | 204 | 489 | 109 |
| 31 Mar 23 | 1,292 | 194 | 488 | 94 |
| 31 Dec 22 | 1,230 | 168 | 489 | 93 |
| 30 Sep 22 | 1,105 | 142 | 456 | 75 |
| 30 Jun 22 | 1,032 | 161 | 422 | 70 |
| 31 Mar 22 | 1,035 | 195 | 404 | 81 |
| 31 Dec 21 | 1,099 | 244 | 400 | 86 |
| 30 Sep 21 | 1,102 | 298 | 369 | 89 |
| 30 Jun 21 | 1,086 | 271 | 361 | 113 |
| 31 Mar 21 | 1,044 | 255 | 339 | 118 |
| 31 Dec 20 | 929 | 228 | 302 | 115 |
| 30 Sep 20 | 840 | 175 | 278 | 118 |
| 30 Jun 20 | 765 | 164 | 245 | 87 |
| 31 Mar 20 | 709 | 154 | 231 | 76 |
| 31 Dec 19 | 663 | 109 | 235 | 91 |
| 30 Sep 19 | 648 | 112 | 230 | 92 |
| 30 Jun 19 | 642 | 124 | 230 | 92 |
| 31 Mar 19 | 612 | 111 | 227 | 94 |
| 31 Dec 18 | 608 | 136 | 220 | 73 |
| 30 Sep 18 | 580 | 141 | 204 | 67 |
| 30 Jun 18 | 557 | 129 | 191 | 88 |
| 31 Mar 18 | 541 | 119 | 203 | 73 |
| 31 Dec 17 | 530 | 114 | 214 | 61 |
| 30 Sep 17 | 537 | 124 | 229 | 35 |
| 30 Jun 17 | 592 | 160 | 260 | 0 |
| 31 Mar 17 | 599 | 178 | 251 | 0 |
| 31 Dec 16 | 583 | 188 | 245 | 0 |
| 30 Sep 16 | 543 | 181 | 220 | 0 |
| 30 Jun 16 | 505 | 161 | 210 | 0 |
| 31 Mar 16 | 465 | 139 | 198 | 0 |
| 31 Dec 15 | 478 | 142 | 194 | 0 |
| 30 Sep 15 | 467 | 152 | 190 | 0 |
| 30 Jun 15 | 486 | 158 | 187 | 0 |
| 31 Mar 15 | 499 | 161 | 195 | 0 |
| 31 Dec 14 | 476 | 140 | 193 | 0 |
| 31 Dec 13 | 472 | 163 | 171 | 0 |
Quality Earnings: 603566 has a large one-off gain of CN¥35.4M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 603566's current net profit margins (9.4%) are lower than last year (16.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603566's earnings have declined by 2.1% per year over the past 5 years.
Accelerating Growth: 603566's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603566 had negative earnings growth (-53.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 603566's Return on Equity (3.9%) is considered low.